Definitive Contract 75N93019C00028
Award Date
9/16/19
Potential Completion Date
5/15/24
Potential Value
$2.3M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
PAI Life Sciences Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Seattle, WA 98102, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
5
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase II Action
Primary Consortia Member
Not listed
Similar Awards
This $441,905 firm fixed-price definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the U.S. Department of Health and Human Services, to PAI Life Sciences Inc. for the development of a prophylactic onchocerciasis (river blindness) vaccine. The contract is designated as a total small business set-aside. PAI Life Sciences, a small disadvantaged business, will collaborate with Thomas Jefferson University and New York Blood...
This is a $444,428 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to PAI Life Sciences Inc., a self-certified small disadvantaged business. The contract is for the development of a Leishmania vaccine, combining parasite and vector components. This contract was designated as a total small business set-aside. PAI Life Sciences has a history of securing federal contracts and grants, particularly from NIAID, for the development of vaccines and...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded PAI Life Sciences Inc. a $597,953 definitive contract to develop late stage adjuvant mimics based on toll-like receptor 4 agonists. As a self-certified small disadvantaged business, this contract was designated as a total small business set aside. PAI Life Sciences will provide products and services to the National Institute of Allergy and Infectious Diseases in support of their program for late stage...
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $299,184 Firm Fixed Price definitive contract to PAI Life Sciences Inc., a self-certified small disadvantaged business, to develop preclinical rabbit immunogenicity data demonstrating the efficacy of a self-adjuvanting and self-amplifying ribonucleic acid (RNA) vaccine platform against human immunodeficiency virus type 1 (HIV-1). This contract was...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $33,273,522 cost-plus-fixed-fee definitive contract to Anivive Lifesciences Inc., a self-certified small disadvantaged business, to develop vaccine candidates for biodefense and emerging infectious diseases. This contract, awarded on June 7, 2024, is part of NIAID's Broad Agency Announcement (BAA) research program and has a completion date of June 1, 2026. The contract...
This federal contract award, valued at $210,507.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to PAI Life Sciences Inc., a self-certified small disadvantaged business, for the "AEROSOLIZED DELIVERY OF ANTI-TUBERCULAR DRUGS" project. The contract is a Definitive Contract with a Firm Fixed Price pricing type. PAI Life Sciences will be the prime contractor, and Research Triangle Institute (RTI International), a non-profit research organization, will...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) awarded a $298,596 definitive contract to Sanaria Inc. of Potomac, MD for Research Type Small Business Innovation Research Program Phase I Action. The contract is a firm fixed price award with a period of performance from August 30, 2022 through April 1, 2024. The place of performance is Potomac, MD and the contract has a total small business set aside...
The federal contract award 75N93019C00029 was granted to KJ Biosciences LLC, a minority-owned, for-profit limited liability company, by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, on September 16, 2019. The $2,944,331.33 cost-plus-fixed-fee contract is for the Phase II advanced development of a novel nanoparticle conjugate vaccine for Salmonella Paratyphi A, under the Small Business Innovation Research (SBIR) program. The contract has a completion date...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. government. The contract, with a ceiling value of $299,943.00, has been awarded to Lifetime Omics, Inc., a minority-owned, woman-owned, and small disadvantaged business. The contract is for research related to SBIR Topic 123, with a completion date of November 30, 2024. The contract is a definitive contract with a firm...
This is a $300,000 firm fixed price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Neovaxsyn Inc., a minority-owned small disadvantaged business. The contract is for research and development to utilize nanoparticles to deliver MPER-based immunogens and elicit broadly neutralizing antibodies against the HIV-1 virus in order to develop a protective vaccine. This contract was awarded under the Small...